Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

CareConekta: study protocol for a randomized controlled trial of a mobile health intervention to improve engagement in postpartum HIV care in South Africa.

Clouse K, Phillips TK, Camlin C, Noholoza S, Mogoba P, Naidoo J, Langford R, Weiss M, Seebregts CJ, Myer L.

Trials. 2020 Mar 12;21(1):258. doi: 10.1186/s13063-020-4190-x.

2.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A.

J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012.

PMID:
32135517
3.

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.

Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD.

Ann Oncol. 2020 Mar;31(3):404-411. doi: 10.1016/j.annonc.2019.11.015. Epub 2019 Dec 9.

4.

The Hospital Readmissions Reduction Program's Impact on Readmissions From Skilled Nursing Facilities.

Smith TB, English TM, Naidoo J, Whitman MV.

J Healthc Manag. 2019 May-Jun;64(3):186-196. doi: 10.1097/JHM-D-18-00035.

PMID:
31999269
5.

Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.

Shafie AA, Ahmad N, Naidoo J, Foo CY, Wong C, Pugh S, Tan KK.

Hum Vaccin Immunother. 2020 Jan 17:1-9. doi: 10.1080/21645515.2019.1701911. [Epub ahead of print]

PMID:
31951782
6.

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y.

J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4.

PMID:
31800340
7.

Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer.

Suresh K, Naidoo J.

Clin Lung Cancer. 2019 Nov 6. pii: S1525-7304(19)30283-9. doi: 10.1016/j.cllc.2019.10.009. [Epub ahead of print] No abstract available.

PMID:
31787546
8.

Successful Treatment of Scar Pain with Scrambler Therapy.

Yarchoan M, Naidoo J, Smith TJ.

Cureus. 2019 Oct 14;11(10):e5903. doi: 10.7759/cureus.5903.

9.

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.

Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, Chan HY, Suri P, Guo H, Merghoub T, Chaft JE, Reuss JE, Tam AJ, Blosser RL, Abu-Akeel M, Sidhom JW, Zhao N, Ha JS, Jones DR, Marrone KA, Naidoo J, Gabrielson E, Taube JM, Velculescu VE, Brahmer JR, Housseau F, Hellmann MD, Forde PM, Pardoll DM, Ji H, Smith KN.

Clin Cancer Res. 2020 Mar 15;26(6):1327-1337. doi: 10.1158/1078-0432.CCR-19-2931. Epub 2019 Nov 21.

10.

Stress and resilience among women living with HIV in Nigeria.

Adamu A, Mchunu G, Naidoo JR.

Afr J Prim Health Care Fam Med. 2019 Oct 23;11(1):e1-e6. doi: 10.4102/phcfm.v11i1.2046.

11.

Therapeutic genome engineering: Implications for South Africa.

Naidoo J, Fok E, Scholefield J.

S Afr Med J. 2019 Sep 10;109(8b):53-57. doi: 10.7196/SAMJ.2019.v109i8b.13850. Review.

12.

Comparative cost analysis of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South Africa.

Simeon K, Sharma M, Dorward J, Naidoo J, Dlamini N, Moodley P, Samsunder N, Barnabas RV, Garrett N, Drain PK.

PLoS One. 2019 Oct 16;14(10):e0223669. doi: 10.1371/journal.pone.0223669. eCollection 2019.

13.

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.

Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC.

Ann Rheum Dis. 2020 Mar;79(3):332-338. doi: 10.1136/annrheumdis-2019-216109. Epub 2019 Sep 20.

PMID:
31540935
14.

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.

Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP.

Am J Respir Crit Care Med. 2019 Sep 15;200(6):e31-e43. doi: 10.1164/rccm.201906-1202ST.

PMID:
31518182
15.

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.

Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J.

J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. Epub 2019 Aug 6.

PMID:
31386608
16.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM, Anagnostou V, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Lin CT, Feller-Kopman D, Lerner AD, Lee H, Shafiq M, Yarmus L, Lipson EJ, Soloski M, Brahmer JR, Danoff SK, D'Alessio F.

J Clin Invest. 2019 Jul 16;130:4305-4315. doi: 10.1172/JCI128654.

17.

Infuse-as-you-go convective delivery to enhance coverage of elongated brain targets: technical note.

Sudhakar V, Naidoo J, Samaranch L, Bringas JR, Lonser RR, Fiandaca MS, Bankiewicz KS.

J Neurosurg. 2019 Jul 12:1-8. doi: 10.3171/2019.4.JNS19826. [Epub ahead of print]

PMID:
31299656
18.

Immune-Related Adverse Events: A Case-Based Approach.

Connolly C, Bambhania K, Naidoo J.

Front Oncol. 2019 Jun 20;9:530. doi: 10.3389/fonc.2019.00530. eCollection 2019. Review.

19.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.

PMID:
31200355
20.

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.

Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y.

J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4.

21.

Genome-wide cell-free DNA fragmentation in patients with cancer.

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.

Nature. 2019 Jun;570(7761):385-389. doi: 10.1038/s41586-019-1272-6. Epub 2019 May 29.

22.

Lung cancer and family-centered concerns.

Feliciano J, Chang A, Venkatraman D, Brooks S, Zagaja C, Ettinger D, Hann C, Naidoo J, Voong R, Hales R, Turner M, Peterson V, Bodurtha J.

Support Care Cancer. 2020 Feb;28(2):497-505. doi: 10.1007/s00520-019-04839-5. Epub 2019 May 7.

PMID:
31065838
23.

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, Suresh K, Hayman J, Hales RK, Alfaifi S, Marrone KA, Levy B, Hann CL, Ettinger DS, Feliciano JL, Peterson V, Kelly RJ, Brahmer JR, Forde PM, Naidoo J.

Clin Lung Cancer. 2019 Jul;20(4):e470-e479. doi: 10.1016/j.cllc.2019.02.018. Epub 2019 Mar 28.

PMID:
31031204
24.

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

PMID:
30865922
25.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

26.

Diagnostic accuracy of the Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study.

Garrett N, Mitchev N, Osman F, Naidoo J, Dorward J, Singh R, Ngobese H, Rompalo A, Mlisana K, Mindel A.

BMJ Open. 2019 Feb 19;9(2):e026888. doi: 10.1136/bmjopen-2018-026888.

27.

Development of a novel frameless skull-mounted ball-joint guide array for use in image-guided neurosurgery.

Sudhakar V, Mahmoodi A, Bringas JR, Naidoo J, Kells A, Samaranch L, Fiandaca MS, Bankiewicz KS.

J Neurosurg. 2019 Feb 15;132(2):595-604. doi: 10.3171/2018.10.JNS182169.

PMID:
30771782
28.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

29.

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J.

Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026. Erratum in: Cardiovasc Res. 2019 Apr 15;115(5):868.

PMID:
30715219
30.

Kinetics and MR-Based Monitoring of AAV9 Vector Delivery into Cerebrospinal Fluid of Nonhuman Primates.

Ohno K, Samaranch L, Hadaczek P, Bringas JR, Allen PC, Sudhakar V, Stockinger DE, Snieckus C, Campagna MV, San Sebastian W, Naidoo J, Chen H, Forsayeth J, Salegio EA, Hwa GGC, Bankiewicz KS.

Mol Ther Methods Clin Dev. 2018 Dec 8;13:47-54. doi: 10.1016/j.omtm.2018.12.001. eCollection 2019 Jun 14.

31.

PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.

Shankar B, Naidoo J.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4034-S4037. doi: 10.21037/jtd.2018.09.46. No abstract available.

32.

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H.

Cancer Res. 2019 Mar 15;79(6):1204-1213. doi: 10.1158/0008-5472.CAN-18-1082. Epub 2018 Dec 20.

33.

Correction to CAN-Mediated Oxidations for the Synthesis of Xanthones and Related Products.

Johnson MM, Naidoo JM, Fernandes MA, Mmutlane EM, van Otterlo WAL, de Koning CB.

J Org Chem. 2019 Jan 4;84(1):472. doi: 10.1021/acs.joc.8b02352. Epub 2018 Dec 13. No abstract available.

PMID:
30543436
34.

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE.

Cancer Res. 2019 Mar 15;79(6):1214-1225. doi: 10.1158/0008-5472.CAN-18-1127. Epub 2018 Dec 12.

35.

An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition.

Naidoo J, Dykema A, D'Alessio F.

J Clin Invest. 2019 Jan 2;129(1):75-77. doi: 10.1172/JCI125800. Epub 2018 Dec 10.

36.

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.

Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, Hales RK, D'Alessio F, Danoff SK, Naidoo J.

J Thorac Oncol. 2019 Mar;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016. Epub 2018 Nov 30.

37.

Stakeholders' experiences in implementation of rapid changes to the South African prevention of mother-to-child transmission programme.

Chiya HW, Naidoo JR, Ncama BP.

Afr J Prim Health Care Fam Med. 2018 Nov 15;10(1):e1-e10. doi: 10.4102/phcfm.v10i1.1788.

38.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

39.

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.

Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D'Alessio F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J.

J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub 2018 Sep 26.

40.

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.

Suresh K, Naidoo J, Lin CT, Danoff S.

Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4. Review.

41.

Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.

Luthra P, Naidoo J, Pietzsch CA, De S, Khadka S, Anantpadma M, Williams CG, Edwards MR, Davey RA, Bukreyev A, Ready JM, Basler CF.

Antiviral Res. 2018 Oct;158:288-302. doi: 10.1016/j.antiviral.2018.08.012. Epub 2018 Aug 23.

42.

Viral Apoptosis Evasion via the MAPK Pathway by Use of a Host Long Noncoding RNA.

Barichievy S, Naidoo J, Boullé M, Scholefield J, Parihar SP, Coussens AK, Brombacher F, Sigal A, Mhlanga MM.

Front Cell Infect Microbiol. 2018 Aug 3;8:263. doi: 10.3389/fcimb.2018.00263. eCollection 2018.

43.

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.

Wills B, Brahmer JR, Naidoo J.

Curr Treat Options Oncol. 2018 Aug 13;19(9):46. doi: 10.1007/s11864-018-0562-9. Review.

PMID:
30101402
44.

Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS.

Naidoo J, Stanek LM, Ohno K, Trewman S, Samaranch L, Hadaczek P, O'Riordan C, Sullivan J, San Sebastian W, Bringas JR, Snieckus C, Mahmoodi A, Mahmoodi A, Forsayeth J, Bankiewicz KS, Shihabuddin LS.

Mol Ther. 2018 Oct 3;26(10):2418-2430. doi: 10.1016/j.ymthe.2018.07.008. Epub 2018 Jul 12.

45.

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, Carr A, Kennedy S, Furney S, Mezynski J, Breathhnach O, Morris P, Grogan L, Hill A, Kennedy S, Crown J, Gallagher W, Hennessy B, Eustace A.

Ther Adv Med Oncol. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297. eCollection 2018.

46.

Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy.

Guo W, Hui X, Alfaifi S, Anderson L, Robertson S, Hales R, Hu C, McNutt T, Broderick S, Naidoo J, Battafarano R, Yang S, Voong KR.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):e239-e248. doi: 10.1016/j.prro.2018.01.004. Epub 2018 Jan 31.

PMID:
29960625
47.

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll DM, Housseau F, Smith KN.

Cancer Immunol Res. 2018 Aug;6(8):888-899. doi: 10.1158/2326-6066.CIR-18-0129. Epub 2018 Jun 12.

48.

Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling.

Baras AS, Naidoo J, Hann CL, Illei PB, Reninger CW, Lauring J.

J Natl Compr Canc Netw. 2018 May;16(5):467-472. doi: 10.6004/jnccn.2017.7203.

PMID:
29752320
49.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

50.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.

Supplemental Content

Loading ...
Support Center